Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Hypothyroidism
Interventions: Armour Thyroid, Levothyroxine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 134
States / cities: Birmingham, Alabama • Bonita, California • Burbank, California + 110 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 66
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Fusion closed loop glucose control system; Device
Lead sponsor: Ideal Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Symbicort pMDI, budesonide pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 160
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more

Conditions: COVID 19
Interventions: HLX71, Placebo; Drug · Other
Lead sponsor: Hengenix Biotech Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Anal Fistula
Interventions: RD2 Ver.02, Saline; Device · Other
Lead sponsor: RedDress Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Weston, Florida • Chicago, Illinois + 6 more

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 36
States / cities: Los Angeles, California • Northridge, California • Sacramento, California + 31 more

Conditions: Acute Pain
Interventions: CR845, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more

Conditions: Crohn's Disease
Interventions: Placebo, ABT-874; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Orange, California • San Diego, California • Hamden, Connecticut + 30 more

Conditions: Noise Induced Hearing Loss
Interventions: SPI-1005 200mg, SPI-1005 400mg, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 5
States / cities: Miami, Florida • Kansas City, Kansas • Charleston, South Carolina + 2 more

Conditions: Dry Eye Disease
Interventions: TL-925, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 4
States / cities: Newport Beach, California • Colorado Springs, Colorado • Indianapolis, Indiana + 1 more

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 147
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 116 more

Conditions: Spondyloarthritis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 27
States / cities: Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Overactive Bladder
Interventions: Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo; Drug
Lead sponsor: Velicept Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 86
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more

Conditions: Osteoporosis in Men
Interventions: Romosozumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Male only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Lakewood, Colorado • Bethesda, Maryland • Albuquerque, New Mexico

Conditions: Scleroderma
Interventions: MEDI-551, Placebo, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 12
States / cities: Loma Linda, California • Redwood City, California • Farmington, Connecticut + 9 more

Conditions: Multiple Sclerosis (MS)
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more

Conditions: Alzheimer Disease
Interventions: lecozotan SR, Donepezil; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis Acute and Progressive
Interventions: Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Venous Thromboembolism (VTE)
Interventions: REGN7508, Apixaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Hialeah, Florida • New York, New York • El Paso, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Alzheimer's Disease
Interventions: T-817MA-H, T-817MA-L, Placebo; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 50
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more

Conditions: Procedural Sedation
Interventions: Remimazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss

A Study of TL-925 as a Treatment for Dry Eye Disease

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Home Based Functional Balance Intervention for Multiple Sclerosis

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability